Form 4: ResMed Director Sells 2,055 Shares Under 10b5-1 Plan

Sentiment:

Insider Transaction Report 26 November 2025 2:40 PM

ResMed director Jan De Witte sold 2,055 shares of common stock for $255 per share as part of a pre-arranged Rule 10b5-1 trading plan.

Worse than expectedA director's sale of company stock, even if pre-planned, is generally viewed as a slightly negative signal by the market, as it reduces the insider's direct equity stake in the company.

Summary

Jan De Witte, a director at ResMed Inc. (RMD), reported a transaction involving the company's common stock.
The transaction occurred on November 25, 2025.
De Witte disposed of 2,055 shares of ResMed Common Stock.
The shares were sold at a price of $255 per share.
Following this transaction, Jan De Witte beneficially owns 4,261 shares of ResMed Common Stock.
The sale was conducted pursuant to a Rule 10b5-1 plan, which was adopted on August 18, 2025.

Sentiment

Score: 4

Explanation: The sale of shares by a director is generally a negative signal, but the fact that it was conducted under a pre-arranged 10b5-1 plan mitigates the immediate negative impact, suggesting it was not an opportunistic sale based on new, undisclosed information.

Negatives

A director, Jan De Witte, sold 2,055 shares of common stock, which can sometimes be interpreted as a lack of confidence, although this transaction was pre-planned.

Future Outlook

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

Shareholders may interpret the director's sale of shares as a slightly negative indicator, potentially leading to minor downward pressure on the stock price, although the 10b5-1 plan context often lessens this impact.

Key Dates

Date	Description
08/18/2025	Date Rule 10b5-1 plan was adopted.
11/25/2025	Date of transaction (sale of common stock).
11/26/2025	Date the Form 4 was signed by the reporting person.

Recommendation

hold

The transaction is a routine insider sale executed under a pre-arranged 10b5-1 plan, which typically indicates a planned liquidity event rather than a reaction to new company-specific information. While an insider sale can be a minor negative signal, this single transaction, given its pre-planned nature, is unlikely to fundamentally alter the investment thesis for ResMed. Investors should continue to evaluate the company based on its broader financial performance and strategic outlook.

Keywords

ResMed, RMD, Insider Sale, Director Transaction, Form 4, 10b5-1 Plan, Stock Sale

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.